CDRD Innovation Fund Archives

Human Health

Somatostatin 2 Receptor (SSTR2) Antagonists for the Prevention of Hypo...

The primary limitation to effective insulin therapy to improve blood sugar control in Type 1 diabetes (T1D) is the risk of hypoglycemia, also known as low blood sugar. Hypoglycemia...

May 25, 2021

Human Health

Discovery and development of novel anti-bacterial drugs...

The primary objective of this project is to confirm the antibacterial activity of compound 043 and 049 analogs in the presence and absence of a synergistic antibiotic and esta...

May 25, 2021

Human Health

Synthetic Lethality – Targeting FEN1 for more selective cancer t...

This project proposes to screen additional CDRD chemical libraries in order to identify a greater number of unique compounds that inhibit FEN1 at low micromolar potency. In paralle...

May 25, 2021

Human Health

Inhibitors of New Delhi Metallo-B-Lactamase 1...

Antibiotic resistance in pathogenic microoganisms is now regarded to be a major threat to human health. One of the most worrying examples of this problem is the rapid emergence and...

May 25, 2021

Human Health

Inhibitors of the CBX7-H3K27me3 epigenetic interaction for castration ...

Prostate cancer is the most commonly diagnosed non-skin cancer in Canadian men, with an estimated 26,500 new cases in 2012. Current treatment options for castration-resistant prost...

May 25, 2021

Human Health

High-throughput Screening in C. elegans for Anthelmintics to treat Fil...

Onchocerciasis (river blindness) and lymphatic filiariasis (elephantiasis) are the most serious human health problems caused by parasitic worms. At least 25 million people are infe...

May 25, 2021

Human Health

Identification of Modulators of the Mesenchymal Progenitor Cell Phenot...

This project's goal is to screen 175,000 compounds to identify agents that promote mesenchymal progenitor (MP) quiescence using increased Hic1 expression as a surrogate marker. 60 ...

May 25, 2021

Human Health

Anti-Influenza Therapeutics – Development of M2 Inhibitors...

The key interim milestone (analog with improved activity/PK) was not achieved. CDRD has decided to discontinue the project and not proceed with remaining tasks in the plan. The pro...

May 25, 2021

Human Health

Development of a synergistic combination of two known drugs for mycoba...

Tuberculosis (TB) is the 2nd leading cause of death by infectious disease in adults worldwide and it is estimated that one third of the world’s population is infected with My...

May 25, 2021

Human Health

Synthetic Platelets...

Platelets, or thrombocytes, are the first responders to vascular injury and are critical to stop bleeding. There is a huge demand for platelets for treatment of patients with bleed...

May 25, 2021

Human Health

Therapeutic Strategies for Huntington’s Disease...

Huntington’s disease (HD) is a devastating neurodegenerative disorder that is characterized by onset of chorea and psychiatric disturbances usually in middle age, accompanied...

May 25, 2021

Human Health

Development of TDP1 inhibitors for use in cancer therapy...

The all too common development of resistance to therapy is a major obstacle to successful cancer treatment. Therefore understanding the mechanisms by which tumours become insensiti...

May 25, 2021

Human Health

Inhibition of protein, protein interactions providing B5neuroprotectio...

The objective of this project was to further the development of NIMoEsh, a peptide that is a potential clinical candidate for the treatment of ischemic stroke. There are currently ...

May 25, 2021

Human Health

Biomarker Development for Clinical Diagnosis of Disease Stage and Resp...

The clinical development of Inflammatory Bowel Diseases (IBD) therapeutics is challenged by the natural waxing and waning of the disease to create large placebo effects that mask c...

May 25, 2021